Deciphera Pharmaceuticals Inc Stock News

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the 40th Annual J.P

Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing well

This article was originally published on TipRanks.com Deciphera Pharmaceuticals (NASDAQ: DCPH) has received marketing authorization for QINLOCK (ripretinib) in the U. The post MHRA Authorizes Decipheras QINLOCK in the U.K. appeared first on Smarter Analyst .

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) have received an average recommendation of Hold from the thirteen analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating on the company. The average []

During the last session, Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH)s traded shares were 11.84 million, with the beta value of the company hitting 1.48. At the end of the trading day, the stocks price was $9.91, reflecting an intraday gain of 8.54% or $0.78. The 52-week high for the DCPH share is $61.92, that puts it down Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) Rose 23.01% From Its 52-Week Low, But YTD Numbers Fell -82.64%. Heres What You Need To Know At This Time Read More »

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 2,830,000 shares, an increase of 36.1% from the November 15th total of 2,080,000 shares. Currently, 7.6% of the companys stock are short sold. Based on an average trading volume of []

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) price on Thursday, December 09, fall -0.69% below its previous days close as a downside momentum from buyers pushed the stocks value to $8.58. A look at the stocks price movement, the close in the last trading session was $8.64, moving within a range at $8.53 and $8.94. The beta value Unlocking Growth Opportunity In Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) Read More »

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH)s traded shares stood at 0.93 million during the last session, with the companys beta value hitting 1.49. At the close of trading, the stocks price was $8.64, to imply an increase of 4.10% or $0.34 in intraday trading. The DCPH shares 52-week high remains $61.92, putting it -616.67% down since that Boom Or Bust: What Does The Future Hold For Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) Stock? Read More »

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Equities research analysts at SVB Leerink lowered their FY2021 earnings estimates for shares of Deciphera Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 30th. SVB Leerink analyst A. Berens now forecasts that the company will earn ($5.29) per share for the year, down from their []

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Piper Sandler cut their FY2021 earnings estimates for Deciphera Pharmaceuticals in a research report issued on Tuesday, November 30th. Piper Sandler analyst C. Raymond now anticipates that the company will post earnings of ($5.35) per share for the year, down from their previous forecast of ($5.09). Piper Sandler has a [] The post Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) to Post FY2021 Earnings of ($5.35) Per Share, Piper Sandler Forecasts appeared first on ETF Daily News .

Wells Fargo & Company MN cut its holdings in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) by 60.6% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 216,114 shares of the companys stock after selling 332,876 shares during the period. Wells Fargo & Company MNs holdings in Deciphera Pharmaceuticals were worth $7,912,000 at the end of the []

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Research analysts at Jefferies Financial Group cut their FY2021 earnings estimates for Deciphera Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 30th. Jefferies Financial Group analyst E. Yang now anticipates that the company will post earnings of ($5.49) per share for the year, down from []

Blueprint Medicines' (BPMC) Ayvakit, which has been approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. However, stiff competition remains a